Cargando…

Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant Enterococci

Vancomycin-resistant enterococci (VRE) account for a large proportion of hospital-acquired infections. Determining optimal treatment of VRE urinary tract infections (UTIs) is challenging. The purpose of this study was to determine if a difference in efficacy or safety exists between linezolid and no...

Descripción completa

Detalles Bibliográficos
Autores principales: Wingler, Mary Joyce, Patel, Neel R., King, S. Travis, Wagner, Jamie L., Barber, Katie E., Stover, Kayla R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628880/
https://www.ncbi.nlm.nih.gov/pubmed/34842791
http://dx.doi.org/10.3390/pharmacy9040175
_version_ 1784607087591948288
author Wingler, Mary Joyce
Patel, Neel R.
King, S. Travis
Wagner, Jamie L.
Barber, Katie E.
Stover, Kayla R.
author_facet Wingler, Mary Joyce
Patel, Neel R.
King, S. Travis
Wagner, Jamie L.
Barber, Katie E.
Stover, Kayla R.
author_sort Wingler, Mary Joyce
collection PubMed
description Vancomycin-resistant enterococci (VRE) account for a large proportion of hospital-acquired infections. Determining optimal treatment of VRE urinary tract infections (UTIs) is challenging. The purpose of this study was to determine if a difference in efficacy or safety exists between linezolid and non-linezolid treatments for VRE UTIs. This retrospective cohort evaluated patients admitted between 1 June 2012–30 November 2017 who were treated for VRE UTI. Patients must have had at least one sign, symptom, or laboratory confirmation of UTI to be included. The primary endpoint of this study was difference in clinical cure between linezolid and non-linezolid treatment options. Secondary endpoints included 30-day recurrence, 30-day infection-related readmission, inpatient mortality, infection-related hospital length of stay (LOS), and time to appropriate therapy. A total of 45 patients (33 linezolid and 12 non-linezolid) were included. Clinical cure occurred in 71.4% linezolid and 58.3% non-linezolid (p = 0.476). No patients had a 30-day infection-related readmission or 30-day recurrence. Of the 45 patients, 6 (13.3%) patients died during admission, and 5 of those deaths were in the linezolid group (p = 1.000). No significant difference was found for clinical cure between linezolid and non-linezolid treatment options for VRE UTIs.
format Online
Article
Text
id pubmed-8628880
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86288802021-11-30 Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant Enterococci Wingler, Mary Joyce Patel, Neel R. King, S. Travis Wagner, Jamie L. Barber, Katie E. Stover, Kayla R. Pharmacy (Basel) Article Vancomycin-resistant enterococci (VRE) account for a large proportion of hospital-acquired infections. Determining optimal treatment of VRE urinary tract infections (UTIs) is challenging. The purpose of this study was to determine if a difference in efficacy or safety exists between linezolid and non-linezolid treatments for VRE UTIs. This retrospective cohort evaluated patients admitted between 1 June 2012–30 November 2017 who were treated for VRE UTI. Patients must have had at least one sign, symptom, or laboratory confirmation of UTI to be included. The primary endpoint of this study was difference in clinical cure between linezolid and non-linezolid treatment options. Secondary endpoints included 30-day recurrence, 30-day infection-related readmission, inpatient mortality, infection-related hospital length of stay (LOS), and time to appropriate therapy. A total of 45 patients (33 linezolid and 12 non-linezolid) were included. Clinical cure occurred in 71.4% linezolid and 58.3% non-linezolid (p = 0.476). No patients had a 30-day infection-related readmission or 30-day recurrence. Of the 45 patients, 6 (13.3%) patients died during admission, and 5 of those deaths were in the linezolid group (p = 1.000). No significant difference was found for clinical cure between linezolid and non-linezolid treatment options for VRE UTIs. MDPI 2021-10-26 /pmc/articles/PMC8628880/ /pubmed/34842791 http://dx.doi.org/10.3390/pharmacy9040175 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wingler, Mary Joyce
Patel, Neel R.
King, S. Travis
Wagner, Jamie L.
Barber, Katie E.
Stover, Kayla R.
Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant Enterococci
title Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant Enterococci
title_full Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant Enterococci
title_fullStr Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant Enterococci
title_full_unstemmed Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant Enterococci
title_short Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant Enterococci
title_sort linezolid for the treatment of urinary tract infections caused by vancomycin-resistant enterococci
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628880/
https://www.ncbi.nlm.nih.gov/pubmed/34842791
http://dx.doi.org/10.3390/pharmacy9040175
work_keys_str_mv AT winglermaryjoyce linezolidforthetreatmentofurinarytractinfectionscausedbyvancomycinresistantenterococci
AT patelneelr linezolidforthetreatmentofurinarytractinfectionscausedbyvancomycinresistantenterococci
AT kingstravis linezolidforthetreatmentofurinarytractinfectionscausedbyvancomycinresistantenterococci
AT wagnerjamiel linezolidforthetreatmentofurinarytractinfectionscausedbyvancomycinresistantenterococci
AT barberkatiee linezolidforthetreatmentofurinarytractinfectionscausedbyvancomycinresistantenterococci
AT stoverkaylar linezolidforthetreatmentofurinarytractinfectionscausedbyvancomycinresistantenterococci